Articles tagged with Tumor Cells
Researchers have identified a novel type of T cell that can selectively target and destroy melanoma tumors. The discovery involves combining cyclophosphamide, an antibody that activates OX40 on T cells, with adoptive T cell transfer to eradicate advanced melanoma tumors in mice.
Researchers discover that breast cancer cells' ability to spread is influenced by the tumor's protein-rich environment as much as genetic changes within the cells. The study reveals that a specific molecular signal in the protein meshwork can initiate metastasis to distant sites, while a healthy environment can even coax healthy cells ...
Researchers at the University of Minnesota have developed a new drug called Minnelide to target and destroy tumor cells in pancreatic cancer. The drug works by inhibiting heat shock protein HSP 70, which aids tumor cell growth, effectively disintegrating the cancer.
Researchers discovered that interleukin-36 may be a useful therapeutic target in the treatment of psoriasis, finding that mice lacking this protein were protected from immune-mediated skin inflammation. Additionally, studies on hypertension revealed that endoplasmic reticulum stress in brain cells contributes to high blood pressure, an...
Melanoma cells can temporarily alter their external characteristics to become invisible to defense cells, allowing them to evade destruction. This knowledge forms an important foundation for improving combination therapies and may also be relevant to treatment with inhibitors of signal transmission in tumor cells.
A new MIT study reveals cellular adhesion molecules critical to cancer's metastasis, offering potential new targets for cancer drug therapy. The researchers found that adhesion tendencies of metastatic cells from different primary tumors were similar, suggesting a shared pathway.
Researchers identified a group of proteins that play a key role in methylation, a process that silences genes in embryonic development. This phenomenon can be accidentally reactivated in tumor cells, leading to the formation of cancer.
Researchers have found that elevated expression of c-Myc amplifies the activity of all expressed genes in tumor cells, leading to increased transcription and proliferation. This discovery provides a simple explanation for how a single protein can have a profound effect in many types of cancer.
Researchers used a new cell technology to treat a patient with a rare type of lung tumor. The treatment, which uses conditionally reprogrammed cells, showed promising results, including some tumor shrinkage and stabilization of tumors after just three months.
Researchers identify a subpopulation of cancer stem cells that display resistance to chemotherapy and contribute to tumor progression. The study suggests a new therapeutic strategy by targeting these cancer stem cells with a combination of standard chemotherapy and signaling pathway inhibitors.
Researchers found that ovarian cancer cells hijack surrounding tissues by activating the HOXA9 gene, which induces TGF-β production and stimulates tumor growth. Blocking TGF-β expression reduced tumor growth, suggesting potential therapeutic targets for treating ovarian cancer.
Ovarian cancer cells activate the HOXA9 gene to create an environment that supports tumor growth. Researchers also found blocking TGF-β expression in ovarian cancer cells significantly reduced tumor growth. Additionally, anti-CTLA therapy and inflammation-reversing treatments may hold promise for treating ovarian cancer and alcoholic l...
Researchers discovered that FAM123A interacts with microtubule-associated proteins regulating cell movement. This interaction is crucial for normal development and life, as well as disease prevention.
The researchers successfully packaged siRNA in a hydrogel complex that can be injected into target tissues, allowing for prolonged control over cell behavior. The technology has the potential to guide stem cells to grow into desired cell types, starve tumors by blocking blood vessel growth, and induce cancer cell death.
Researchers have identified melanoma stem cells marked by the enzyme ALDH, which exhibit high tumorigenicity and resistance to chemotherapy. Targeting these cells with a new therapy could boost the effectiveness of existing drugs.
A UT Southwestern Medical Center study reveals that glioblastoma multiforme (GBM) recurs due to slower-growing 'cancer stem-like' cells. Researchers identified these cells as a potential target for future therapies, offering new hope for treatment.
A new study published in the FASEB Journal reveals that a molecule called 'flightless' significantly helps control cell movement through tissues. By increasing the stickiness of cells to underlying tissue, flightless slows their movement and may prevent cancer from spreading from one tissue to another.
Researchers identified 38 prognostic subnetworks of interacting genes that predict cancer progression in chronic lymphocytic leukemia. The study helps define how CLL evolves over time, becoming more aggressive and deadly.
Researchers discovered that tumor cells release chemokine CCL2, which docks onto endothelial cells and activates the CCR2 receptor, making them permeable. This pathway enables tumor cells to migrate and metastasize.
Researchers create high-throughput flow-through optical microscope to classify rare breast cancer cells in blood samples, boasting a throughput of 100,000 cells per second. The technology demonstrates real-time identification of rare cancer cells with a record low false-positive rate.
Researchers develop a new method to isolate and grow cancer cells, which can aid in understanding how cancer spreads and ultimately fighting it. The soft fibrin substrate promotes the growth of tumorigenic cells, making them more efficient at causing tumors.
Researchers showcased the breadth of zebrafish research at an international conference, focusing on cancer and nicotine dependence. A study found that mid-differentiated cells play a key role in tumor growth, challenging traditional views on cancer stem cells. Another study used zebrafish to identify novel candidate genes involved in n...
Researchers discovered that pancreatic cancer cells produce a protein that tricks the immune system into helping cancer growth. Blocking this protein may lead to effective treatments for pancreatic cancer. The findings suggest restoring the antitumor properties of a patient's immune system could be a therapeutic strategy.
Researchers at NYU School of Medicine have made a key discovery about the progression of pancreatic cancer, revealing how it escapes immune detection. By targeting a protein called GM-CSF, they found that immune cells can be unleashed to attack and halt tumor development.
A recent study found that targeting the JAK1 and JAK2 tyrosine kinase pathways can increase tumor cell susceptibility to natural killer cell-mediated death. Pharmacological inhibition of these pathways was shown to enhance tumor cell killing, making them a promising target for cancer therapy.
Researchers at IRB Barcelona have identified specific combinations of errors in cell integrity processes as crucial to initiating tumors. The study reveals that genomic instability alone is not sufficient for tumor development and highlights the need for further investigation into cancer's complex origins.
Researchers found that Skp2 E3 ligase promotes Herceptin resistance in breast cancer by activating the Akt kinase, which also regulates glucose metabolism. The study suggests that blocking Skp2 could inhibit glycolysis and provide a new approach to cancer treatment.
Scientists have identified the Mitochondrial Pyruvate Carrier (MPC), a universal carrier that transports pyruvate into mitochondria. This discovery could lead to a better understanding of how cancer cells produce energy and potentially develop new treatments.
Researchers at Massachusetts General Hospital identified a tumor-propagating cell required for growth in a pediatric muscle tumor model. Another type of differentiated tumor cell must first colonize new areas to prime an environment for metastatic growth.
Researchers identified a cell surface protein ganglioside GD2 that flags breast cancer stem cells as potent tumor-generating cells. A small molecule drug triptolide inhibits GD3 synthase, essential to GD2 production, and stymies cancer growth in preclinical tests.
Researchers have discovered that children's brain tumors preserve characteristics of the normal cells from which they originate, offering new hope for effective treatments. The study found that tumour malignancy is linked to cellular origin and time of tumour development, improving prospects for targeted therapies.
Researchers have developed a potent new drug called Lys05 that kills tumor cells in mouse models by clogging their recycling system. This approach has shown promise as a single-agent anti-tumor therapy with minimal toxicity to healthy cells.
A new Stanford study reveals that the cells sloughed off from a cancerous tumor into the bloodstream are genetically diverse and may require different treatments. The research found that these cells can express genes that predict their response to therapy, highlighting the need for personalized treatment approaches.
Researchers discovered a population of low-PSA prostate cancer stem cells that are resistant to hormone therapy and chemotherapy. These cells can differentiate into other cancer cell types and have long-term tumor-propagating capacity.
Researchers have identified a molecule, PDE4, that plays a key role in regulating the division of tumor cells and blood vessel growth in lung cancer. By blocking PDE4, they were able to significantly reduce tumor growth in laboratory experiments and mouse models.
Researchers have discovered that NKCC1 protein facilitates the movement of glioblastoma cells, which are notoriously aggressive and deadly. The study also suggests that a cheap FDA-approved drug, bumetanide, could slow cell migration and contain tumor spread.
Researchers have discovered that the NKCC1 protein may hold key to understanding how glioblastoma, the deadliest type of brain cancer, moves and invades healthy brain tissue. Blocking NKCC1 with a cheap FDA-approved drug slows movement of glioblastoma cells, suggesting a potential new approach to treat this aggressive cancer.
Researcher Carlos Martino explores how fluctuations in static and radiofrequency magnetic fields impact biochemical reactions. His work shows that low-level fields can inhibit tumor growth and modulate cellular proliferation, offering potential for a therapy based on weak radiofrequency fields.
A recent study published in PNAS contradicts the prevailing belief that basal-like cells are responsible for invasive tumors. Luminal-like cells, previously thought to lack stem cell properties, have been found to be highly tumorigenic and capable of generating larger tumors than their basal-like counterparts.
Researchers identify non-classical oncogenes critical for leukemia cell survival and develop a strategy targeting these molecules, potentially reducing toxicity of current treatments. Dual inhibition of PI3K subtypes supports cancer cell death in mice and human tumor cells.
Researchers created transgenic mice with light-emitting lymphatic vessels to study tumor cell dissemination. The technique detects lymph node invasion by tumor cells, providing a unique tool for studying inflammation and metastasis.
Researchers have identified metastasin as a crucial protein that helps stop tumor cells from spreading. By understanding how metastasin binds to motor proteins, scientists can develop drugs to block this interaction and prevent tumor cell proliferation.
A study led by experts at the University of Nottingham has discovered a link between chromosomal abnormalities and survival rates in children with brain cancer. The research identified increased copies of chromosome 1q25 as associated with poorer outcomes, paving the way for a new diagnostic test.
Cancer researchers employed game theory to study the physics of tumor evolution under stress conditions. They found that modifying their framework accounted for heterogeneous stress patterns, leading to emergent cooperative outcomes between cooperator and cheater cells.
Researchers at Winship Cancer Institute developed a technique to remove cancer cells' defenses against radiation by disabling their ability to repair DNA. The experimental method uses RNA molecules that shut down genes needed for DNA repair, making brain and lung cancer cells more sensitive to X-ray radiation.
Brain-tumor cells infected with a cancer-killing virus release CCN1, which initiates an antiviral response that reduces viral replication and limits its cytolytic efficacy. This mechanism may help control viral infections and improve oncolytic viral therapy for glioblastoma.
Research reveals that BRG1 gene mutations render tumor cells unresponsive to hormones like retinoic acid and steroids, leading to continued growth and spreading.
Researchers at Rensselaer Polytechnic Institute found a previously unknown link between breast cancer cells and the stroma. Cadherin-23, a new molecule, helps connect cancerous tumor cells to healthy tissue, facilitating invasive growth.
Researchers have created a universal approach to personalized cancer therapy based on T cells, offering a highly adaptable and effective treatment option. The system uses engineered T cells capable of targeting multiple tumor antigens simultaneously or sequentially, significantly extending conventional CAR approaches.
Scientists at Scripps Research Institute have uncovered a self-sustaining signaling circuit in breast cells that leads to cancer. This circuit is triggered by the activation of MEK/ERK and IKK/NF-kB pathways, which maintain the malignant state of tumor cells.
A new microfluidic device can isolate target cells much faster than existing devices, using a soft membrane with nanoscale pores to guide fluid and bring cells in contact with antibodies. This technology could be used for point-of-care diagnostics and personalized medicine applications, such as cancer diagnosis.
Researchers found that inhibiting telomerase triggers alternative lengthening of telomeres (ALT) in cancer cells, leading to increased expression of PGC-1ß gene. Targeting PGC-1ß weakens mitochondria function and enhances anti-telomerase therapy.
Researchers at MGH Cancer Center have discovered a potential treatment target for KRAS-mutant colon cancer, which may lead to new strategies for treatment-resistant tumors. Targeting TAK1 and BMP pathways may induce tumor cell death, offering hope for patients with KRAS-dependent colon cancers.
Researchers at Boston University have created a 3D model that simulates the growth of cancer tumors, suggesting that softening of cancer cells accelerates proliferation and extends lifetime, leading to rapid tumor growth. The study provides a new quantitative approach to understanding tumor development based on mechanical properties.
Scientists have developed a new method using DNA sequencing to identify cancer cells that can be targeted by the immune system. By analyzing genetic data from cancer cells and normal cells, researchers were able to identify specific mutated genes whose altered proteins trigger immune system attacks.
Researchers at Sanford-Burnham identified a molecular switch, controlled by protein kinase C-epsilon, that enables melanoma cells to resist chemotherapy. High levels of PKC-epsilon in melanoma are associated with poor prognosis and increased tumor-promoting activity.
A team of researchers has identified a potential new therapeutic target for the treatment of glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. They found that protein SULF2 is expressed in primary human GBM tumors and cell lines, and its expression is associated with abnormal activation of signaling pathways down...
Researchers found that Pannexin1 helps closely pack together tumor cells, forming large multicellular tissues. The protein sets off a chain reaction involving ATP and receptors, ultimately remodeling the actin network to increase forces between cells, driving them to bind more tightly.
Researchers studied the role of immune responses in oncolytic adenovirus therapy and found that CD8+ T cells mediate antitumor efficacy. The study proposes a new therapeutic regime combining oncolytic adenovirus with immunotherapy.
Researchers at Scripps Research Institute found that a cell surface protein called CDCP1 protects tumor cells from apoptosis and promotes metastasis. The team identified plasmin as the key enzyme responsible for cleaving CDCP1, which triggers a signaling cascade blocking apoptosis and enabling cancer cells to colonize distant organs.